Cara Therapeutics (TVRD) Competitors

Cara Therapeutics (NASDAQ:TVRD) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Does the MarketBeat Community favor TVRD or AUPH?

Aurinia Pharmaceuticals received 576 more outperform votes than Cara Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave Cara Therapeutics an outperform vote.

Company	Underperform	Outperform
Cara Therapeutics	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%

Does the media prefer TVRD or AUPH?

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Cara Therapeutics. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 4 mentions for Cara Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.50 beat Cara Therapeutics' score of 0.58 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, TVRD or AUPH?

Cara Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of TVRD or AUPH?

44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has better earnings and valuation, TVRD or AUPH?

Cara Therapeutics has higher earnings, but lower revenue than Aurinia Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
Aurinia Pharmaceuticals	$247.30M	4.29	-$78.02M	$0.28	28.07

Do analysts recommend TVRD or AUPH?

Cara Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 124.14%. Aurinia Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 46.31%. Given Cara Therapeutics' higher possible upside, equities research analysts clearly believe Cara Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is TVRD or AUPH more profitable?

Cara Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Cara Therapeutics' return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Therapeutics	N/A	N/A	N/A
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%

Summary

Aurinia Pharmaceuticals beats Cara Therapeutics on 8 of the 13 factors compared between the two stocks.